Feb 3 2010
BSD Medical Corp. (NASDAQ:BSDM) reports publication of a news article by
the Journal of the National Cancer Institute on the evolving role of
hyperthermia in cancer therapy titled, “International Study of
Hyperthermia Spurs Hope in U.S.” (J. Natl. Cancer Inst. 2010 102: 79-81;
doi:10.1093/jnci/djp530). The article reviewed the history of
hyperthermia in cancer therapy, including the challenges faced by
hyperthermia advocates and the progress that has been made in addressing
these challenges. The article stated that, “Successful use of targeted
heat therapy with chemotherapy in treatment of soft-tissue sarcoma has
given U.S. advocates of local hyperthermia new hope that the treatment
they so believe in will now be taken seriously.”
“With all the efforts to find new treatments that are more
tumor selective and less toxic, it is astonishing that an existing
treatment that is relatively tumor selective, has a low toxicity, and
that in clinical studies has been shown to result in considerable
benefit, receives so little attention.”
The article reviewed the EORTC/NCI Phase III multicenter randomized
study on 341 high risk soft-tissue sarcoma patients, which showed a
significant improvement in disease-free survival and demonstrated that
patients were 30% more likely to be alive and cancer-free almost three
years after starting treatment if hyperthermia was added to their
chemotherapy treatment. All institutions who participated in the study,
including Duke University Medical Center, used the BSD 2000 Deep
Regional Hyperthermia System to administer hyperthermia.
The article quoted Rolf
Issels, M.D., Ph.D., a professor of medical oncology at Klinikum
Grosshadern Medical Center at the University of Munich and the lead
researcher on the Phase III sarcoma study, who stated that the findings,
“provide a new standard treatment option, and we believe they are likely
to change the way many specialists treat these tumors.” Dr. Issels
discussed the impact of the results of the Phase III sarcoma study on
the field of hyperthermia and concluded, “…the implications of these
findings are more far-reaching.” “This is also the first clear evidence
that targeted heat therapy adds to chemotherapy.”
The author of the article, Renee Twombly, interviewed leading
hyperthermia researchers for the publication. Two leading hyperthermia
researchers from Duke, Dr. Zeljko Vujaskovic and Dr. Mark
Dewhirst, discussed the history and clinical application of
hyperthermia. Jacoba van der Zee, M.D., Ph.D., the Erasmus MC–Daniel den
Hoed Cancer Center in Rotterdam, a leader in the field of hyperthermia,
stated that, “With all the efforts to find new treatments that are more
tumor selective and less toxic, it is astonishing that an existing
treatment that is relatively tumor selective, has a low toxicity, and
that in clinical studies has been shown to result in considerable
benefit, receives so little attention."
Elizabeth A. Repasky, Ph.D., of Roswell Park Cancer Institute, Buffalo,
N.Y., and president of the Society for Thermal Medicine stated, "We are
on a verge, I think, of a major new adjuvant cancer therapy that will
not replace chemotherapy or radiation, but will make them work a lot
better." The Society for Thermal Medicine promotes research into the
clinical application of hyperthermia.
SOURCE BSD Medical Corporation